Several abnormalities of carbohydrate metabolism common to a variety of endocrine and nutritional disorders have been shown recently to be associated with a high plasma concentration of nonesterified fatty acids (NEFA). For example, starvation or carbohydrate deprivation in the normal individual produces not only a marked impairment of carbohydrate tolerance, but also results in elevated levels of plasma NEFA (1) (2) (3) . The coincident development of impaired carbohydrate tolerance and decreased sensitivity to insulin in association with elevated fasting plasma NEFA levels is seen in obesity (4-6), maturity-onset diabetes mellitus (7) (8) (9) , acromegaly (5, 10, 11), pregnancy (12, 13) , and subjects given exogenous human growth hormone (14) (15) (16) (17) . Randle, Garland, Hales, and Newsholme (18) have recently suggested that elevated plasma NEFA levels may be causally related to the impaired carbohydrate tolerance and decreased insulin sensitivity seen in these conditions, and have proposed the term "glucose-fatty-acid cycle" to denote the interactions between glucose and fatty acid metabolism in peripheral tissues responsible for the control of the blood glucose and fatty acid levels.
Considerable evidence from in vitro studies in several laboratories (18) (19) (20) (21) (22) can be marshalled in support of this intriguing concept, but to date there has been no demonstration that the circulating level of plasma NEFA influences either the rate of glucose utilization or the insulin responsiveness of the intact organism.' The present study was undertaken to determine whether an acute and sustained elevation of the plasma nonesterified fatty acid level in man can, in itself, impair carbohydrate tolerance and decrease the sensitivity of the peripheral tissues to insulin.
Methods-
Experimental procedure. A simple experimental technique has been devised that rapidly raises the plasma NEFA level for a prolonged period and does not require the use of either endocrine or nutritional influences, which in themselves impair carbohydrate tolerance. The experimental procedure, hereafter referred to as the fat meal-heparin regimen, is based on the following observations: 1) marked chylomicronemia develops 3 to 5 hours after a fat meal (23) ; 2) chylomicrons are substrates for tissue lipoprotein lipase (24) ; and 3) intravenous heparin activates lipoprotein lipase and its release into the circulation (24, 25) . The fat meal-heparin regimen used in this study consisted of the ingestion of a 60-g fat meal of emulsified corn oil (60 g corn oil, 60 ml water, 15 g egg white, 6 ml vanilla extract, 0.5 g salt, and 0.4 ml sodium cyclamate) followed in 3 hours by the intravenous administration of 50 mg of heparin sodium.
Twelve normal subjects and five patients wvith mild diabetes mellitus according to the criteria of Fajans and Conn (26) radioimmunoassay method of Schalch and Parker (31) . Plasmas assayed for insulin and human growth hormone were stored at -200 C until used. Since pancreatic insulin secretion could not be measured directly in these studies, the area circumscribed by the plasma insulin response curve has been used as an index of insulin secretion and is expressed as microunit-minutes per milliliter.
Results
Effect of the fat meal-heparin regimen on plasma levels of NEFA, glucose, insulin, and growth hormone. Three normal subjects were studied on two or more occasions after an overnight fast to determine the effect of the fat mealheparin regimen on plasma NEFA, glucose, insulin, and growth hormone (Figure 1 ). Three hours after the ingestion of the fat meal, the plasma Effect of fat meal-heparin regimen on carbohydrate tolerance in normal subjects. The carbohydrate tolerance in twelve normal subjects was 2014 the administration of a fat meal and heparin regimen (Table I ). The fat meal-heparin regimen resulted in a marked reduction (> 45%o) in carbohydrate tolerance in six subjects, a moderate reduction (> 16%o) in three others, and no reduction in the remaining three subjects (G.L., C.S., C.W.). When compared to the mean control K value, the average decrease in the glucose disappearance rate after the fat meal-heparin regimen was 36.1%o, dropping from a mean base-line value of 2.74 + 0.14 to a mean experimental value of 1.75 + 0.27%o per minute (Figure 3 ). This decrease is significant with a p value < 0.02. All three subjects that showed no reduction (two actually showed an increase) in the glucose disappearance rate during the fat meal-heparin study had markedly elevated fasting plasma NEFA levels on the day of the control study after the administration of a fat meal and intravenous heparin. The average insulin secretion (as previously defined) in response to 25 g of iv glucose was 1,878 + 159 MU-minutes per ml during the control studies, and increased significantly (p < 0.05) to 2,352 + 231 MU-minutes per ml during the fat meal-heparin studies.
The degree of impairment of glucose tolerance in these normal subjects closely paralleled the increase in plasma NEFA level. The regression line, plotted by the method of least squares, relating the glucose utilization rate seen after the fat meal-heparin regimen and the corresponding increase in plasma NEFA level is recorded in Figure 4 . The coefficient of correlation (r) equals -0.733 and is significant with a p value of < 0.005.
Effect of fat meal-heparin regimen on carbohydrate tolerance in mild diabetes mellitus. Similar studies were performed on five mild diabetics who were controlled on diet alone and had normal fasting blood sugar and plasma NEFA levels (Table  II) . During the control studies, the average glucose disappearance rate of the diabetic group was 1.24 + 0.16%o per minute ( Figure 5 ), approximately 45%o of the control value for normal subjects. After the fat meal-heparin regimen, the mean plasma NEFA level rose from the fasting value of 578 + 84 /uEq per L to 2,101 + 471 uEq per L, but there was no further impairment in carbohydrate tolerance (K = 1.24 + 0.18). It should be noted that the reduced glucose disappearance rate in normal individuals on the fatheparin regimen (K = 1.75 + 0.27) approaches the disappearance rate in these diabetic subjects. The plasma insulin response in diabetic patients during the control study was 1,861 ± 417 uU-minutes per ml, only slightly less than that seen in normal individuals, and it was not significantly altered during the fat meal-heparin period (2,318 ± 167 MU-minutes per ml).
Temporal relationship between the fatty acid mobilizing activity and the insulin antagonistic effect of growth hormone. Since these studies indicate that an increase in the level of circulating NEFA may be associated with impaired carbohydrate tolerance and insulin responsiveness, the temporal relationship between the fatty acid mobilizing activity of human growth hormone (HGH) and its well-known insulin antagonistic action was explored. After initial base-line studies, repeat intravenous glucose tolerance tests were performed on seven normal subjects on different days at 10, 60, and 120 minutes after the intravenous administration of 5 mg of human growth hormone (Table III) . Ten minutes after the administration of growth hormone (Figure 6 ), its acute "insulin-like effect" produced an average increase of 32% in the glucose disappearance rate over the mean control value for the same subjects (p < 0.005). Sixty minutes after HGH administration, the average glucose disappearance rate returned to approximately the control value. The average plasma NEFA levels 10 and 60 minutes after HGH administration were insignificantly different from the mean control value. One hundred twenty minutes after the administration of HGH, the glucose disappearance rate decreased 48%o from the control value (p < 0.005) while at the same time the plasma NEFA level rose 103%o over the mean fasting value (p < 0.005).
Discussion
The results of this study support the proposal of Randle and his associates (18) lating level of nonesterified fatty acids may be an mit conclusions regarding the changes induced by important factor in regulating the glucose toler-the fat meal-heparin regimen on the metabolism of ance and insulin responsiveness of the intact or-glucose by specific organ systems, in particular, ganism. The rapid intravenous glucose tolerance striated muscle, adipose tissue, and liver. On the test, used in this study for assessing glucose disap-basis of in vitro studies, however, increased NEFA pearance rates in the total organism, does not per-concentrations would be expected to decrease the glucose metabolism has not been systematically studied, but it has been reported that the intravenous infusion of sodium octanoate at a rate sufficient to produce a significant ketonemia did not affect net splanchnic glucose production (33) . The temporal correlation between the appearance of increased plasma NEFA levels and decreased glucose disappearance rates that follow the intravenous injection of human growth hormone is consistent with the concept that the insulin antagonistic effect of growth hormone is secondary to its lipolytic activity. The severity of impairment of glucose tolerance after growth hormone administration, however, is greater than would have been predicted from the plasma NEFA level, using as a basis of comparison the relationship between acute elevation in plasma NEFA level and the associated decrease in glucose disappearance rate seen after the fat meal-heparin regimen (Figure 4) ceptor, e.g., albumin, was added to the incubation medium to keep the intracellular fatty acid concentration low (32) . Several recent studies have further indicated that it is not the fatty acids per se but rather the fatty acid acyl CoA derivatives that are directly responsible for the changes in enzyme activities resulting in the alterations in carbohydrate and lipid metabolism seen in conditions characterized by high plasma fatty acid levels (35) (36) (37) . Summary A simple method has been described for producing an acute and sustained elevation of the plasma nonesterified fatty acid (NEFA) level. The results of this study indicate that in man an elevation in plasma NEFA concentration may be associated with an impaired glucose tolerance and decreased target organ sensitivity to insulin. The degree of impairment in carbohydrate tolerance is closely correlated with the elevation in the plasma NEFA level. After growth hormone administration the rise in plasma NEFA is temporally related to the appearance of insulin antagonism.
These studies support the concept that several of the abnormalities of carbohydrate metabolism associated with growth hormone administration, starvation, pregnancy, obesity, and diabetes mellitus may be a consequence, at least in part, of the elevated nonesterified fatty acid levels characteristic of these conditions.
